» Articles » PMID: 23801422

Statin Therapy in Patients with Atypical Chest Pain and Mild-to-moderate Coronary Stenosis on 64-slice Multidetector Coronary Computed Tomography; a Retrospective Propensity Score Matching Analysis

Overview
Journal Eur Radiol
Specialty Radiology
Date 2013 Jun 27
PMID 23801422
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The effect of computed tomography (CT)-guided statin therapy on patients with atypical chest pain and mild-to-moderate coronary artery disease has not been elucidated yet.

Methods: A total of 1,952 patients who had 1-69 % stenosis on CT were reviewed retrospectively. After propensity score matching, 643 patients who were prescribed statins after CT (statin users) and 643 patients without statin therapy (statin non-users) were compared. Major cardiovascular events included all-cause death, acute coronary syndrome and stroke.

Results: During a median of 42 months' follow-up, all-cause death was reported in 17 patients (1.3 %), of whom 6 (0.9 %) were statin users and 11 (1.7 %) statin nonusers. Major cardiovascular events developed in 6.1 % in the statin user group and 5.6 % in the statin non-users (P = 0.812). When evaluated according to plaque subtypes, statins showed significant benefit in patients who had non-calcified or mixed plaque (HR 0.47, 95 % CI 0.22-1.01, P = 0.047). However, in patients with calcified plaques, statins had no benefit in reducing adverse events (P = 0.620).

Conclusion: In most patients with mild-to-moderate coronary artery stenosis on CT, statin therapy has no beneficial effect on reducing adverse events. However, in patients with non-calcified or mixed plaques, statin therapy showed a significant benefit.

Key Points: • Multidetector CT now identifies numerous subjects with mild-to-moderate coronary stenosis. • Statin therapy has little beneficial effect on patients with calcified plaques. • However, statins reduce adverse events in those with non-calcified or mixed plaques.

Citing Articles

Effect of long-term intensive cholesterol control on the plaque progression in elderly based on CTA cohort study.

Sun T, Wang Y, Wang X, Hu W, Li A, Li S Eur Radiol. 2022; 32(7):4374-4383.

PMID: 35226154 DOI: 10.1007/s00330-022-08594-w.


Effects of cardiac medications for patients with obstructive coronary artery disease by coronary computed tomographic angiography: results from the multicenter CONFIRM registry.

Schulman-Marcus J, Hartaigh B, Giambrone A, Gransar H, Valenti V, Berman D Atherosclerosis. 2014; 238(1):119-25.

PMID: 25479800 PMC: 4277901. DOI: 10.1016/j.atherosclerosis.2014.11.007.

References
1.
. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339(19):1349-57. DOI: 10.1056/NEJM199811053391902. View

2.
Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

3.
Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

4.
Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

5.
Wanahita N, Chen J, Bangalore S, Shah K, Rachko M, Coleman C . The effect of statin therapy on ventricular tachyarrhythmias: a meta-analysis. Am J Ther. 2010; 19(1):16-23. DOI: 10.1097/MJT.0b013e3181e9087a. View